Wyniki wyszukiwania

1

Pharmacogenetic considerations of anticoagulant medication

100%

Miklosz J., Kalaska B., Mogielnicki A.

Journal of Physiology and Pharmacology

|

2018

|

tom 69

|

nr 4

2

Artykuł dostępny w postaci pełnego tekstu - kliknij by otworzyć plik

Direct factor Xa inhibitor in the prevention of thromboembolism

84%

Meretskyi V., Meretska I., Pertsovych V.

Health Problems of Civilization

|

2018

|

tom 12

|

nr 4

Venous thromboembolism is the third most common cause of vascular death after myocardial infarction and stroke, and is associated with considerable morbidity and premature mortality. The incidence of the most serious consequence of venous thromboembolism, fatal pulmonary embolism, ranges from 0.01% to 5% among hospitalised medical patients with multiple risk factors, and is currently considered the commonest avoidable cause of hospital death. Rivaroxaban is a small-molecule factor Xa inhibitor that belongs to a new class of direct oral anticoagulant agents that directly inhibit single enzymes in the coagulation pathway. Rivaroxaban has many advantages over vitamin K antagonists and unfractionated heparin and may become an alternative to traditional anticoagulant agents in patients at risk for thromboembolism. Moreover, antidotes exist and are in the progress of development, both specific and non-specific, for the treatment of overdose or side effects, including bleeding.

3

Antithrombotic medications and their impact on fibrin clot structure and function

84%

Undas A., Zabczyk M.

Journal of Physiology and Pharmacology

|

2018

|

tom 69

|

nr 4

4

A vitamin K epoxide reductase-oxidase complex gene polymorphism [-1639G>A] and interindividual variability in the dose-effect of vitamin K antagonists

67%

Stepien E., Branicka A., Ciesla-Dul M., Undas A.

Journal of Applied Genetics

|

2009

|

tom 50

|

nr 4

399-403

A daily dose of vitamin K. antagonists (VKAs) may vary and its range depends on various interrelated factors. Low responsiveness to VKA (defined as a failure to achieve a target international normalized ratio [INR]) is associated with polymorphisms of the vitamin K epoxide reductase-oxidase complex gene (VKORC1). A highly prevalent promoter single-nucleotide polymorphism (VKORC1-1639 G>A, rs17878363) impairs VKORC1 expression and determines the interindividual variability of the target INR. We studied 57 patients receiving oral anticoagulation, including 50 subjects treated with acenocoumarol (mean dose: 5.7+2.3 mg/day) and 7 treated with warfarin (mean dose: 9.6±4.2 mg/day). The indications for the use of oral anticoagulant therapy were as follows: deep-vein thrombosis (N = 23); pulmonary embolism (N = 20); arterial thrombosis (N = 5); stroke (N = 4); atrial fibrillation with transient ischemic attacks (N = 2), and history of multiple thromboembolic events (N = 3). Identification of the VKORC1 genomic variation was performed using DNA sequencing methods. The prevalence of the mutated allele (VKORC1-1639A) was 41%. The VKORC1 -1639G allele carriers required a higher daily dose of acenocoumarol (5.9+1.9 mg) than the noncarriers (4.1+3.3 mg; P < 0.001). All of 5 low responded (who failed to achieve a target INR using standard dose requirements of VKAs) were homozygous for the 1639G allele. Low responders did not differ from good responders with respect to age, gender, and body mass index. Our findings suggest the potential benefits from pharmacogenetic testing, and provide evidence that the VKORCl -1639 G>A gene polymorphism may explain at least in part the low responsiveness to acenocoumarol.

5

Cloning and expression of a new recombinant thrombolytic and antithrombotic agent - a staphylokinase variant

67%

Kowalski M., Brown G., Bieniasz M., Oszajca K., Chabielska E., Pietras T., Szemraj Z., Makandjou-Ola E., Bartkowiak J., Szemraj J.

Acta Biochimica Polonica

|

2009

|

tom 56

|

nr 1

41-53

To develop a more potent antithrombin agent with thrombolytic and antiplatelet properties, a new staphylokinase (SAK) variant was constructed. The kringle 2 domain (K2) of tissue type-plasminogen activator (t-PA) containing a fibrin-specific binding site (i), the RGD sequence (Arg-Gly-Asp) for the prevention of platelet aggregation (ii) and the antithrombotic agent - hirulog (iii) was assembled to the C-terminal part of recombinant staphylokinase (r-SAK). cDNA for the hybrid protein SAK-RGD-K2-Hirul was cloned into Pichia pastoris pPIC9K yeast expression vector. The introduction of K2 t-PA, the RGD sequence and hirulog into the C-terminus of r-SAK did not alter the staphylokinase activity. We observed a higher clot lysis potency of SAK-RGD-K2-Hirul as evidenced by a faster and more profound lysis of 125I-labeled human fibrin clots. The potency of thrombin inhibition by the hirulog C-terminal part of the recombinant fusion protein was almost identical to that of r-Hir alone. These results suggest that the SAK-RGD-K2-Hirul construct can be a more potent and faster-acting thrombolytic agent with better antithrombin and antiplatelet properties compared to r-SAK and SAK-RGD-K2-Hir.

6

Heparin-induced thrombocytopenia in a patient with massive lung embolism and left-sided pneumonia: a case report

67%

Doboszynska A., Rozek M., Swietlik E., Tomaszewska I.

Journal of Physiology and Pharmacology. Supplement

|

2007

|

tom 58

|

nr 5

7

Badanie ultrasonograficzne układu naczyniowego jamy brzusznej

43%

Huynh E., Porter E. G., Berry C. R.

Weterynaria po Dyplomie

|

2019

|

tom 20

|

nr 5

Ograniczanie wyników

Pharmacogenetic considerations of anticoagulant medication

Direct factor Xa inhibitor in the prevention of thromboembolism

Antithrombotic medications and their impact on fibrin clot structure and function

A vitamin K epoxide reductase-oxidase complex gene polymorphism [-1639G>A] and interindividual variability in the dose-effect of vitamin K antagonists

Cloning and expression of a new recombinant thrombolytic and antithrombotic agent - a staphylokinase variant

Heparin-induced thrombocytopenia in a patient with massive lung embolism and left-sided pneumonia: a case report

Badanie ultrasonograficzne układu naczyniowego jamy brzusznej